Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

The PRN Notebook

Available CME

Welcome to The PRN Notebook CME Program, brought to you by the Physicians’ Research Network (PRN) and the Medical Society of the State of New York (MSSNY). Below please find a list of our enduring programs where, as a PRN Member (membership is free) you can obtain free CME (and MOC for physicians). Each program has the accompanying video and program slides to help you obtain the requisite CME/MOC.

If you are not a member, just register here.

  • HIV Remission in a Woman of Mixed Race with AML and HIV: The New York Patient

    Marshall Glesby MD, PhD and Deborah Persaud, MD, PhD

    First there was the Berlin patient, then the London patient, and now, we have the New York patient who is a mixed-race cisgender woman cured of HIV.  There are other important differences between this new cure including the use of cord blood in her stem cell transplant.  Don’t miss this important description of her case, as presented by Drs. Marshall Glesby and Deborah Persaud.

  • Long COVID in People With and Without HIV

    Keri N. Althoff, PhD, MPH

    What are the post-acute sequelae of SARS-CoV-2 that define long COVID? Is it different in people living with HIV? This presentation by Keri Althoff will help you understand the phenotypes and possible mechanisms of long COVID. Dr. Althoff will also focus on the manifestations of long COVID in people living with HIV.

  • Prostate Cancer in Cisgender Gay and Bisexual Men and Trans Women

    Channa A. Amarasekera, MD

    Is the experience of diagnosis and treatment of prostate cancer different in gay and bisexual men than it is in straight men?  Dr. Channa Amarasekera, the director of the first Gay and Bisexual Men’s Urology Program in the country, thinks so. In this important presentation, you will learn about his efforts to improve the urologic care experience, outcomes and quality of life for cisgender men who identify as gay or bisexual.  You will also appreciate how HIV infection influences prostate cancer screening and treatment.

  • Preventing Anal Cancer: Results from the ANCHOR Study

    Joel M. Palefsky, MD, FRCP (C)

    We have known for a long time that the incidence of anal cancer associated with HPV infection is higher amongst people living with HIV. But now, with the results of the ANCHOR study, we know that identification of anal high-grade squamous intraepithelial lesions (HSIL) through high resolution anoscopy (HRA) followed by destruction of these pre-cancerous lesions has been proven to prevent progression to anal cancer. In this presentation, Joel Palefsky returns to PRN to share the exciting results of the ANCHOR study and its implications for a new standard of care in people living with HIV.

  • CROI 2022: Updates on HIV Treatment & Prevention and SARS-COV-2

    Roy M. Gulick, MD, MPH

    Every year the Conference on Retrovirology and Opportunistic Infections (CROI) is packed with important new information in HIV medicine and again this year includes COVID-19 as well. Don’t miss this engaging review by Trip Gulick on CROI 2022 highlights in HIV cure, new drugs, treatment strategies and prevention, as well as the latest on SARS CoV-2 and COVID-19.

  • Healthy Aging with HIV in the Context of COVID-19

    Giovanni Guaraldi, MD

    When you really think about it, healthy aging is the ultimate goal of HIV management.  In the context of polypharmacy so often seen in older people, and in the midst of the the COVID-19 pandemic, Giovanni Guaraldi will help you understand the principles of HIV geriatric medicine, assess biological age with frailty, appreciate different models of HIV care in older adults, and maintain optimal antiretroviral therapy while deprescribing polypharmacy.

  • Healthy Aging with HIV in the Context of COVID-19

    Giovanni Guaraldi, MD

    When you really think about it, healthy aging is the ultimate goal of HIV management.  In the context of polypharmacy so often seen in older people, and in the midst of the the COVID-19 pandemic, Giovanni Guaraldi will help you understand the principles of HIV geriatric medicine, assess biological age with frailty, appreciate different models of HIV care in older adults, and maintain optimal antiretroviral therapy while deprescribing polypharmacy.

  • HIV Testing: Time for a Change, and the Reasons Why

    Bernard M. Branson, MD

    Pre-exposure prophylaxis, especially long-acting PrEP, affects the laboratory diagnosis of HIV.  And the current diagnostic algorithm needs some updating anyway. In this presentation, Bernie Branson discusses the aging HIV diagnostic algorithm and ways to improve it, the difference between HIV RNA for diagnosis vs. monitoring, and which tests are necessary before initiating ART.

  • Updates on COVID-19 Treatment and HIV/COVID-19 Coinfection

    Rajesh T. Gandhi, MD

    Evidence-based treatment options for COVID-19 in non-hospitalized patients are expanding. In this presentation Raj Gandhi will discuss the most current approaches to treating non-hospitalized patients with COVID-19, as well as important considerations for hospitalized patients.  Additionally, Dr. Gandhi will summarize our current understanding of COVID-19 in people living with HIV.

  • Update on Genetic Prediction of Future Cardiovascular Disease

    Wendy S. Post, MD, MS

    In addition to genetic testing that we can order for clinical purposes, our patients are increasingly turning to direct-to-consumer (DTC) genetic testing on their own, to explore their ancestry. But if one of these DTC tests also shows increased risk for cardiovascular disease (CVD), then your patient’s next likely stop will be with you to discuss the relative importance of this discovery. Are you ready for this? Dr. Wendy Post, an expert on CVD and HIV/AIDS, is also immersed in the study of the genetics of CVD. In this presentation, Dr. Post will review what is currently known about the genetic risks for CVD, and how lifestyle modification can influence the genetic risk for CVD. She will also review the strengths and limitations of polygenic risk scores for CVD and commercially available genetic testing.

  • EACS 2021: Highlights from the European AIDS Conference

    Jürgen Rockstroh, MD

    2021 marks the 18th year of the European AIDS Conference, this year in London.  Juergen Rockstroh, a past president of EACS,  provides compelling conference updates, focussing on epidemiology, diagnostics, treatments, aging and the impact of COVID-19 on people living with HIV in Europe.

  • Organ Transplantation for People Living with HIV/AIDS: Advances and Challenges

    Sapna A. Mehta, MD, FIDSA

    We all know that some of our patients living with HIV may one day need a heart, liver or kidney transplant—but do all of our HIV positive patients know that they can be organ donors? In her comprehensive and up-to-date presentation, Sapna Mehta reviews the current studies evaluating outcomes of HIV positive organ use for HIV positive recipients.  It’s time to spread the word.

  • HIV/HCV Coinfection

    Brianna Norton, DO, MPH

    How does HIV coinfection affect the epidemiology, progression and treatment of hepatitis C (HCV)?  In this presentation, Brianna Norton will bring you up-to-date on the natural progression of liver disease in HIV/HCV coinfected individuals and discuss the differences in HCV epidemiology among HIV/HCV coinfected versus HCV monoinfected individuals. Dr. Norton will also discuss drug-drug interactions between HIV antiretrovirals and HCV directly-acting-antivirals.

  • Anal Cancer Prevention

    Stephen E. Goldstone, MD, FACS

    Diagnosis and prevention of anal cancer has long been an important element of HIV Medicine. In this presentation, Stephen Goldstone returns to speak on the most recent data demonstrating success of the HPV vaccine.  He will also discuss wide-field ablation of high-grade squamous epithelial lesions (HSIL) and whether treating HSIL is reducing anal cancer in those at highest risk.

  • COVID-19 Vaccine Progress and Predicaments

    Kristen Marks, MD

    Up-to-date knowledge of COVID-19 vaccines, newer vaccine options under development, and the evidence for and against booster shots have never been more important during this pandemic. Kristen Marks will discuss these issues as well as adverse events secondary to COVID-19 vaccines, and common vaccine management questions.

  • Highlights from the Virtual IAS Conference on HIV Science 2021

    W. David Hardy, MD, AAHIVS

    This program presented by David Hardy is a review of highlights from the Virtual IAS Conference on HIV Science 2021, including clinically relevant advances in antiretroviral therapy, metabolic effects, as well as investigational agents for HIV treatment and prevention.

  • Advances in COVID-19 Management

    Jürgen Rockstroh, MD

    What clinicians and researchers have learned over these past 18 months during the COVID-19 pandemic is of critical importance to us now and may help us change outcomes for this as well as future pandemics.  Jügen Rockstroh’s thoughtful presentation will provide an update on COVID-19 epidemiology, diagnostics, treatments and vaccines from a European perspective.

  • Inflammation, Morbidity and Mortality in Treated HIV: Roles of Asymptomatic CMV and Sex Differences

    Peter W. Hunt, MD

    Chronic inflammation caused by herpesviruses (especially CMV) and by sex differences, leads to end-organ morbidities in HIV disease despite optimal treatment of HIV. In this presentation, Peter Hunt explores the causes and consequences of persistent immune activation in treated HIV infection, including its impact on age-related morbidity and mortality as well as HIV persistence.

  • Liver Disease in the Face of COVID-19

    Elizabeth C. Verna, MD, MSc

    Does COVID-19 infection contribute to liver disease? And does pre-existing liver disease affect the course of COVID-19 outcomes?  In this presentation, Elizabeth Verna addresses these important questions and also explains how the COVID-19 pandemic has impacted the care of patients with chronic liver disease including the initiatives regarding viral hepatitis elimination.

  • Got anything for the Cough? Treatments for Early COVID-19

    Davey Smith, MD

    Despite the vaccine roll-out, new cases of COVID-19 persist; hence we still need tounderstand and optimize the treatments available to us, as well as those in development.  In this comprehensive presentation,  Davey Smith discusses current treatments as well as antiviral drugs in development for COVID-19.

  • HIV-1 bNAbs: Looking Ahead

    Marina Caskey, MD

    Marina Caskey provides a comprehensive update of broadly neutralizing antibodies (bNAbs) in the treatment and prevention of HIV.  Learn the latest on outcomes from recent engineered HIV bNAbs clinical trials, prevention efficacy studies, as well as new HIV bNAb delivery systems entering clinical evaluation.

  • HIV and COVID-19 in New York City: a Population-Level Analysis

    Sarah Braunstein, PhD, MPH

    We all worry about co-infections in our patients living with HIV/AIDS and their potential outcomes.  This is especially true in the COVID-19 pandemic. In this presentation, Dr. Sarah Braunstein, from the New York City Department of Health and Mental Hygiene, will discuss the intersection of HIV and COVID-19 in New York City and the growing evidence for higher risk of adverse COVID-19-related outcomes among people with HIV.

  • R4P 2021: Updates on the HIV Pre-Exposure Prophylaxis Pipeline

    Craig W. Hendrix, MD

    Every two years, HIV Research for Prevention (R4P) meets internationally and focuses solely on prevention modalities, technologies, and strategies.  In this thought-provoking presentation, Craig Hendrix reviews the highlights of HIV R4P, including long-acting PrEP, on-demand PrEP, and multipurpose prevention technologies

  • CROI 2021: Updates on HIV Treatment & Prevention and SARS-COV-2

    Roy M. Gulick, MD, MPH

    Every year the Conference on Retrovirology and Opportunistic Infections (CROI) is packed with important new information in HIV medicine and this year including COVID-19 as well. Don’t miss this engaging review by Trip Gulick on CROI 2021 highlights in HIV cure, new drugs, treatment strategies, and prevention, as well as the latest on SARS CoV-2 and COVID-19.

  • State of the LA-ART: New Drug Delivery Technologies in HIV Treatment and Prevention

    Charles W. Flexner, MD

    Long-acting antiretroviral formulations for HIV treatment and prevention - if nobody has asked you about why they are important and how they work, don’t miss this program, which will help you prepare.  Nanoformulations, erodable and non-erodable implant formulations, and other mechanisms for making drugs work longer are on the way, and Charles Flexner will discuss all of them in this engaging program.

  • Vaccines for the Prevention of COVID-19: An Unprecedented Need: An Unprecedented Response

    Susan J. Little, MD

    In this crucial and timely presentation, Susan Little compares and contrasts currently available mrna vaccines to each other and to the pending adenovirus and protein subunit vaccines in development.  Dr. Little covers other important topics including vaccine hesitancy, limits on currently available data, and how to report adverse experiences in your patient population during post-licensure surveillance.

  • Fighting a Moving Target: SARS-CoV-2 Evolution and Viral Escape in COVID-19

    Jonathan Z. Li, MD, MMSc

    From our experience with HIV, we all appreciate the impactof viral mutations.  In this PRN presentation, Jonathan Li discusses the evolution, viral escape, persistence, reinfection and novel strains of Sars-CoV-2 and how they are affecting the current COVID-19 pandemic.

  • Addressing Behavioral Health Needs During the COVID-19 Pandemic: Patients with HIV and the Health Care Team

    Francine Cournos, MD

    The Covid-19 pandemic has caused much distress – not just for our patients, but for our fellow healthcare providers as well.  But how can we differentiate mental distress from mental disorder? In this presentation, Dr. Francine Cournos will share findings from peer-reviewed literature pertaining to the behavioral health needs of patients with HIV and their health care providers alike.  She will also share simple behavioral health strategies, including the World Health Organization Pyramid of Mental Health Services to the COVID-19 pandemic.

  • Prevention of New Pediatric HIV Infections: A Work in Progress

    Elaine J. Abrams, MD

    What progress has been made world-wide in the prevention of new pediatric HIV infections?  How has the COVID-19 pandemic impacted HIV services for pregnant women and infants?  In this presentation by Elaine Abrams, we will gain insight into these critical questions along with an understanding of optimal antiviral regimens for use during pregnancy and breastfeeding, as well as gaps along the cascade of care for prevention of vertical HIV transmission.

  • Ending the HIV Epidemic in New York City During the Covid-19 Pandemic

    Anisha Gandhi, PhD, MPH

    How has the COVID-19 pandemic impacted efforts to end the HIV epidemic in New York City? In this presentation, Anisha Gandhi will discuss the most up-to-date epidemiology in New York City along with current strategies to end the epidemic.

  • Controversies in Testosterone Treatment 2020 in Cisgender and Transgender Men

    Todd T. Brown, MD, PhD

    Testosterone is prescribed frequently for hypogonadism in cisgender men living with HIV, aging cisgender men, and for gender-affirming therapy in transgender men.  But do we fully understand the benefits?  And what do we really know about the risks?  This presentation by Todd Brown will bring you up to date on the outcomes from pertinent studies including the Testosterone Trials (TTrials) in older cisgender men and what is presently known about the potential risks in transgender men.

  • Multidimensional Challenge of COVID-19: Including COVID-19 and HIV

    Rajesh T. Gandhi, MD

    With the waxing and waning of COVID-19 infections, it is vital to stay up-to-date — especially with our patients living with HIV. 
    In this presentation, Raj Gandhi will review the most recent data on clinical manifestations and treatment considerations for COVID-19 in the general population, including people living with HIV.

  • A Big Year for New HIV Prevention Choices

    Craig W. Hendrix, MD

    The more effective PrEP options we have, the more we will reduce barriers to adherence and usage -- and the more we can succeed at reducing HIV transmission. People will benefit with improved success at preventing new infection. In this comprehensive review, Dr. Hendrix will present an update on microbicides, vaginal rings, long-term injectables, and other advances in new drug development and delivery that will expand on the existing options for PrEP.

  • Progress Towards Developing an Effective HIV Cure

    Steven G. Deeks, MD

    The chronic management of HIV disease has advanced so far already, do even need a cure? Join us for this exciting presentation by Steve Deeks addressing the needs for a broadly scalable cure for HIV, as well as research approaches that may help us achieve this ever-elusive yet long-sought goal.

  • Testing for HIV and COVID-19: It Is What It Is

    Bernard M Branson MD

    One of the greatest challenges with the COVID 19 pandemic has been the availability, speed, and accuracy of diagnostic testing. In this presentation, Bernard Branson will discuss both HIV and COVID 19 testing. With COVID 19, you will learn to understand the fundamentals of laboratory tests as well as appreciate the role for serology testing in identifying exposure. As we have learned with HIV testing, it can and must get better. In fact, with recent advances in HIV testing, it may be time for a new HIV diagnostic algorithm. Learn which parameters affect the accuracy of tests for both COVID 19 and HIV.

  • Atherosclerotic Cardiovascular Disease in HIV: Special Focus on Transgender and Cisgender Women

    Mabel Toribio, MD, PhD

    We all know that our patients living with HIV are at higher risk for atherosclerotic cardiovascular disease. But data on women has been lacking. In this presentation by Mabel Toribio, you will learn to describe mechanisms of heightened atherosclerotic cardiovascular disease among people living with HIV, along with prevention and treatment strategies. Dr. Toribio will be presenting her most current research, which includes under-represented populations – in particular, transgender and cisgender women.

  • Outpatient Anal Cancer Screening in the Era of COVID-19

    Joel Palefsky, MD, FRCP(C)

    The COVID 19 pandemic has complicated every aspect of medical care including the screening and prevention of anal cancer.  Are there barriers to screening that are new? Do we need to be taking special precautions in the screening and care of our patients living with HIV and HPV in the face of the COVID pandemic?  In this presentation, Joel Palefsky provides an update on the epidemiology of anal HPV infection, detection, and treatment of pre-cancerous lesions among people living with HIV, as well as an update on the ANCHOR study – all in the face of the COVID 19 pandemic.

  • COVID-19 and HIV

    Roy M. Gulick, MD, MPH

    We live with the constant fear of a resurgence of the COVID 19 pandemic.  When our patients living with HIV ask us about COVID19 and its impact on them, what do we say and how can we best guide them?  This comprehensive review of the clinical features and treatment of COVID 19 in the setting of HIV infection by Dr. Roy (Trip) Gulick will address these important questions, vital to our patients’ well-being - whether we see them in-person or virtually.

  • Highlights from the 23rd International AIDS Conference: AIDS 2020

    W. David Hardy, MD, AAHIVS

    This program presented by David Hardy is a review of highlights from the 2020 International Aids Conference, including current antiretroviral therapy, ART and pregnancy, metabolic effects, investigational treatments, as well as HIV prevention and cure.  Dr. Hardy also discusses issues surrounding COVID-19 that were covered as part of the 2020 International Aids Conference.

  • Antiretroviral Therapy for Treatment and Prevention: Beyond Daily Oral Therapy - A New Frontier

    Martin H. Markowitz, MD

    Please join us for a presentation by Dr. Markowitz on the current recommendations for cART, a review of recent long-acting cabotegravir and rilpivirine data, and the exciting use of broadly neutralizing antibodies in the treatment and prevention of HIV.

  • Biomedical Prevention for COVID-19: Vaccines, MABs and Lessons from HIV

    Mark J. Mulligan, MD, FIDSA

    Dr. Mark Mulligan, Director, NYU Langone Vaccine Center describes the current landscape of COVID vaccine research.

    This program is up-to-the-minute with a focus on New York City’s current role in COVID prevention, the emerging science during this public health emergency, and how we can learn from our HIV experience to manage the current pandemic.

  • COVID-19 Pandemic: Update, Successes and Challenges

    Wafaa El-Sadr, MD, MPH, MPA

    Lessons we have learned from the HIV response can guide us moving forward as the new COVID-19 pandemic continues to expand and evolve. In this program, Wafaa El-Sadr, well known for her innovative work in HIV here in New York and around the world, uses her rich background experience to examine the dynamics of COVID19, scrutinize the challenges and successes of the various responses so far, identify populations disproportionately affected, and anticipate future needs with a steady eye on the science, public health and healthcare systems necessary for a more effective response to this devastating new pandemic.

  • Antiretroviral Therapy for Treatment and Prevention: Beyond Daily Oral Therapy - A New Frontier

    Martin H. Markowitz, MD

    Please join us for a presentation by Dr. Markowitz on the current recommendations for cART, a review of recent long-acting cabotegravir and rilpivirine data, and the exciting use of broadly neutralizing antibodies in the treatment and prevention of HIV.

  • HIV Prevention Outreach in the 2020s: Grindr™, Gonorrhea, and HIV PrEP

    Martin Hoenigl, MD, FECMM

    Do Grindr™  users take more risks? Are Grindr™ users more likely to serosort? Dr. Martin Hoenigl will answer these questions. He will also cover novel ways to use geosocial mobile apps to better reach marginalized populations at risk for HIV/STIs and to promote testing and PrEP use.

  • COVID-19 epidemic in Europe: What have we learned? And does underlying HIV-infection make a difference?

    Jürgen Rockstroh, MD

    What European clinicians and researchers have recently learned in these unprecedented times is of critical importance to us now and may help us change future outcomes.

The PRN Notebook

image

TRANSMISSION

Transmission, Diagnosis and the HIV Epidemic

View Article List

image

PROGRESSION

Pathogenesis and Progression of HIV Disease.

View Article List

image

MANAGEMENT

Treatment, Resistance and Management of HIV/AIDS

View Article List

image

COMPLICATIONS

Complications and Comorbidities

View Article List

image

COINFECTIONS

Coinfections and Opportunistic Infections

View Article List

Visit The PRN Notebook